Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Required: CD19 positive

Must have received: systemic anticancer therapy — relapsed/refractory

patient must meet the definition of relapse/refractory before enrollment

Cannot have received: systemic anticancer therapy

Exception: within 5 half-lives of the agent or attending clinical trials 4 weeks prior to beginning CC312

Systemic anticancer therapy within 5 half-lives of the agent or attending clinical trials 4 weeks prior to beginning CC312

Cannot have received: radiotherapy

Exception: within 2 weeks before the study entry

Treatment with radiotherapy within 2 weeks before the study entry

Cannot have received: CAR-T cell therapy

Exception: within 3 months before the study entry

Treatment with CAR-T within 3 months before the study entry

Cannot have received: anti-CD19 directed therapy

Exception: eligible only if tumor cells have been shown to express CD19 after completing the CD19-directed therapy

Patients with prior treatment with anti-CD19 directed therapies are eligible only if their tumor cells have been shown to express CD19 after completing the CD19-directed therapy

Cannot have received: autologous stem cell transplant

Exception: B-NHL patient that received autologous stem cell transplant 6 months prior to study screening

B-NHL patient that received autologous stem cell transplant 6 months prior to study screening

Cannot have received: organ or allogeneic stem cell/bone marrow transplant

Exception: historically received organ or allogeneic stem cell/bone marrow transplant

historically received organ or allogeneic stem cell/bone marrow transplant

Cannot have received: transplantation treatment

Exception: B-ALL patients that received transplantation treatment within 3 months prior to enrollment

B-ALL patients that received transplantation treatment within 3 months prior to enrollment in the study